Invesaro

Stocks Comparison

Bristol Myers Squibb vs Johnson & Johnson: revenue, profit, margins and growth compared

Bristol Myers Squibb brought in $48.2B of revenue in fiscal 2025, Johnson & Johnson $94.2B in fiscal 2025. Revenue changed by -0.2% at Bristol Myers Squibb and +6.0% at Johnson & Johnson on the year before, so Johnson & Johnson grew faster. Bristol Myers Squibb kept 14.6% of its revenue as net profit, Johnson & Johnson 28.5%. Free cash flow was $12.8B at Bristol Myers Squibb and $19.7B at Johnson & Johnson.

Side by side, latest fiscal year

BMYJNJ
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 28, 2025)
Revenue$48.2B$94.2B
Revenue growth-0.2%+6.0%
Net income$7.1B$26.8B
Net margin14.6%28.5%
Free cash flow$12.8B$19.7B
Free cash flow margin26.7%20.9%
Earnings per share (diluted)$3.46$11.03
Cash$10.2B$19.7B
Debt$44.8B$41.4B
Price to earnings18.224.6
Market value$128.4B$653.6B
Dividend yield3.96%1.90%
Rank by revenue in sector#16 of 523 · Health care#9 of 523 · Health care

Over the years

Revenue
BMY FY2018: $22.6BBMY FY2019: $26.1BBMY FY2020: $42.5BBMY FY2021: $46.4BBMY FY2022: $46.2BBMY FY2023: $45BBMY FY2024: $48.3BBMY FY2025: $48.2BJNJ FY2018: $81.6BJNJ FY2019: $82.1BJNJ FY2020: $82.6BJNJ FY2021: $78.7BJNJ FY2022: $80BJNJ FY2023: $85.2BJNJ FY2024: $88.8BJNJ FY2025: $94.2BFY18FY19FY20FY21FY22FY23FY24FY25
BMY $48.2BJNJ $94.2B
Net income
BMY FY2018: $4.9BBMY FY2019: $3.4BBMY FY2020: -$9BBMY FY2021: $7BBMY FY2022: $6.3BBMY FY2023: $8BBMY FY2024: -$8.9BBMY FY2025: $7.1BJNJ FY2018: $15.3BJNJ FY2019: $15.1BJNJ FY2020: $14.7BJNJ FY2021: $20.9BJNJ FY2022: $17.9BJNJ FY2023: $35.2BJNJ FY2024: $14.1BJNJ FY2025: $26.8BFY18FY19FY20FY21FY22FY23FY24FY25
BMY $7.1BJNJ $26.8B
Net margin
BMY FY2018: 21.8%BMY FY2019: 13.2%BMY FY2020: -21.2%BMY FY2021: 15.1%BMY FY2022: 13.7%BMY FY2023: 17.8%BMY FY2024: -18.5%BMY FY2025: 14.6%JNJ FY2018: 18.8%JNJ FY2019: 18.4%JNJ FY2020: 17.8%JNJ FY2021: 26.5%JNJ FY2022: 22.4%JNJ FY2023: 41.3%JNJ FY2024: 15.8%JNJ FY2025: 28.5%FY18FY19FY20FY21FY22FY23FY24FY25
BMY 14.6%JNJ 28.5%
Revenue growth
BMY FY2019: +15.9%BMY FY2020: +62.6%BMY FY2021: +9.1%BMY FY2022: -0.5%BMY FY2023: -2.5%BMY FY2024: +7.3%BMY FY2025: -0.2%JNJ FY2019: +0.6%JNJ FY2020: +0.6%JNJ FY2021: -4.7%JNJ FY2022: +1.6%JNJ FY2023: +6.5%JNJ FY2024: +4.3%JNJ FY2025: +6.0%FY19FY20FY21FY22FY23FY24FY25
BMY -0.2%JNJ +6.0%
Free cash flow
BMY FY2018: $6.1BBMY FY2019: $7.4BBMY FY2020: $13.3BBMY FY2021: $15.2BBMY FY2022: $11.9BBMY FY2023: $12.7BBMY FY2024: $13.9BBMY FY2025: $12.8BJNJ FY2018: $18.5BJNJ FY2019: $19.9BJNJ FY2020: $20.2BJNJ FY2021: $19.8BJNJ FY2022: $17.2BJNJ FY2023: $18.2BJNJ FY2024: $19.8BJNJ FY2025: $19.7BFY18FY19FY20FY21FY22FY23FY24FY25
BMY $12.8BJNJ $19.7B

Fiscal years as each company reports them; the two may end in different months.

Questions about Bristol Myers Squibb and Johnson & Johnson

Which is bigger by revenue, Bristol Myers Squibb or Johnson & Johnson?

Johnson & Johnson is bigger by revenue: $94.2B in fiscal 2025, against $48.2B for Bristol Myers Squibb in fiscal 2025.

Which keeps more of its revenue as profit, Bristol Myers Squibb or Johnson & Johnson?

Bristol Myers Squibb had a net margin of 14.6% in fiscal 2025; Johnson & Johnson had 28.5% in fiscal 2025.

Which grew revenue faster, Bristol Myers Squibb or Johnson & Johnson?

In their latest fiscal years revenue changed by -0.2% at Bristol Myers Squibb and +6.0% at Johnson & Johnson.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies